5-Amino-1MQ Oral (50mg capsule)
5-Amino-1-Methylquinolinium (5-Amino-1MQ) is an orally active inhibitor of the enzyme NNMT (Nicotinamide N-methyltransferase). NNMT inhibition increases NAD+ levels in adipocytes, promoting lipolysis and metabolic activity. Preclinical data show a reduction in body fat and an increase in energy expenditure.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full 5-Amino-1MQ encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
5-Amino-1MQ inhibits the NNMT enzyme in adipocytes → increased intracellular NAD+ → activation of SIRT1/SIRT3 sirtuins → increased mitochondrial β-oxidation of fatty acids + browning of white adipose tissue. Concurrently, it reduces SAM-dependent methylation associated with lipogenesis.
Quick Start
- Form: 50mg capsule — no reconstitution required.
- Typical research dose: 50–150 mg daily, divided into 1–3 doses.
- Administration time: Morning (or split morning/midday), with or without food.
- Research stage: Preclinical — limited human data.
Research Dosing — 5-Amino-1MQ Oral
Route: Oral (per os) | Frequency: 1–3 times daily
| Week | Dose | Amount |
|---|---|---|
| Weeks 1–2 | 50 mg (50,000 mcg) | 1 x 50mg capsule (morning) |
| Weeks 3–4 | 100 mg (100,000 mcg) | 2 x 50mg capsules (morning + midday) |
| Weeks 5–8 | 150 mg (150,000 mcg) | 3 x 50mg capsules (morning + midday + afternoon) |
Dosing is extrapolated from preclinical data. Split the dose into 1–3 administrations per day. The small molecule profile supports oral bioavailability.
Related compounds
Protocol Overview
- 5-Amino-1MQ is a small molecule inhibitor of NNMT — an enzyme that converts nicotinamide to N-methylnicotinamide, reducing NAD+ levels.
- NNMT inhibition → increased NAD+ → activation of SIRT1/SIRT3 → increased mitochondrial function in adipocytes.
- In mice on a high-fat diet, administration of 5-Amino-1MQ reduced body weight by ~7% and induced browning of white adipocytes (browning effect) without changing food intake (Neelakantan et al., 2018).
Dosing Protocol
- Start with 50mg daily (1 capsule in the morning) for the first 2 weeks.
- Increase to 100mg (morning + midday) for weeks 3–4.
- If well-tolerated, increase to 150mg daily (3 capsules).
- An 8-week cycle is typically followed by a 4-week break.
- Break between cycles: A 4-week break between cycles is recommended.
Washout & Cycle Restart
When can I restart?
A 4-week break between cycles is recommended.
Minimum wait period: 4 weeks
Storage Instructions
- Store at room temperature (15–25 °C).
- Away from moisture and light.
- Keep sealed between uses.
Important Notes
- ⚠️ Human clinical data is very limited.
- NNMT inhibition may affect nicotinamide metabolism — monitor B3/NAD+ levels.
- Not an approved medication — research compound only.
- Avoid during pregnancy/breastfeeding.
Potential Benefits & Side Effects
Potential Benefits:
- Body fat reduction (preclinical)
- Increased NAD+ in adipocytes
- Browning of white adipose tissue
- Increased energy expenditure
- Oral administration — ease of use
Potential Side Effects:
- Limited human data
- Potential gastrointestinal discomfort
- Theoretical risk: changes in B3 vitamin metabolism
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hepatotoxicity (preclinical)
As an NNMT inhibitor, 5-amino-1MQ has shown hepatotoxicity at high doses in rodents. No human safety studies exist.
📄 Biochem Pharmacol 2020References
- Neelakantan H. et al. — Selective and membrane-permeable small molecule inhibitors of NNMT (2018) — Discovery of 5-Amino-1MQ as an NNMT inhibitor — anti-obesity effects in mice.
View Source - Kannt A. et al. — NNMT as a target for obesity and metabolic syndrome — Role of NNMT in adipose tissue metabolism and therapeutic prospects.
View Source - Kraus D. et al. — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (2014) — Genetic inhibition of NNMT — reduction of obesity in animal models.
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — NNMT inhibitor
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →